Neurodegenerative Disorders, Alzheimer’s and Parkinson’s – References

Matthew C.L. Phillips

Current: Neurologist and Director of Neurology, Waikato Hospital, Hamilton, New Zealand

Past: Queen’s University, Kingston, Canada; Flinders University, Adelaide, Australia; Queen Elizabeth Hospital, Adelaide, Australia; Royal Melbourne Hospital, Melbourne, Australia; Cairns Hospital, Cairns, Australia

Dr. Phillips is a full-time public clinical and research neurologist. His team conducted world-first randomized trials involving a ketogenic diet

References

Neurodegenerative Disorders, Alzheimer’s and Parkinson’s – References

  1. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2024;20:3708–3821.
  2. Parkinson’s Foundation. https://www.parkinson.org/understanding-parkinsons/statistics.  Accessed 21 March 2025.
  3. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7:e105–25.
  4. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939–53.
  5. Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL. et al. Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinsons Dis. 2020;6:15.
  6. Cannon JR, Greenamyre JT. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci. 2011;124:225–50.
  7. Phillips MC. Metabolic strategies in healthcare: a new era. Aging Dis. 2022;13:655–72.
  8. Raudino F. Non-cognitive symptoms and related conditions in the Alzheimer’s disease: a literature review. Neurol Sci. 2013;34:1275–82.
  9. Ishii M, Iadecola C. Metabolic and non-cognitive manifestations of Alzheimer’s disease: the hypothalamus as both culprit and target of pathology. Cell Metab. 2015;22:761–76.
  10. Chaudhuri KR, Healy DG, Schapira AHV, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235–45.
  11. Jellinger KA. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord. 2012;27:8–30.
  12. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.
  13. Henriques AD, Benedet AL, Camargos EF, Rosa-Neto P, Nóbrega OT. Fluid and imaging biomarkers for Alzheimer’s disease: where we stand and where to head to. Exp Gerontol. 2018;107:169–77.
  14. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601.
  15. Algarni MA, Stoessl AJ. The role of biomarkers and imaging in Parkinson’s disease. Expert Rev Neurother. 2016;16:187–203.
  16. Miklossy J, Taddei K, Martins R, Escher G, Kraftsik R, Pillevuit O, et al. Alzheimer disease: curly fibers and tangles in organs other than brain. J Neuropathol Exp Neurol. 1999;58:803–14.
  17. Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson’s disease. Mov Disord. 2009;24:793–800.
  18. Mullane K, Williams M. Alzheimer’s disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery? Biochem Pharmacol. 2020;177:113945.
  19. Alfaidi M, Barker RA, Kuan W-L. An update on immune-based alpha-synuclein trials in Parkinson’s disease. 2025;272:21.
  20. Howick J, Koletsi D, Ioannidis JPA, Madigan C, Pandis N, Loef M, et al. Most healthcare interventions tested in cochrane reviews are not effective according to high quality evidence: a systematic review and meta-analysis. J Clin Epidemiol. 2022;148:160–9.
  21. Phillips MCL, Picard M. Neurodegenerative disorders, metabolic icebergs, and mitohormesis. Transl Neurodegener. 2024;13:46.
  22. Monzel AS, Enríquez JA, Picard M. Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction. Nat Metab. 2023;5:546–62.
  23. Picard M, Shirihai OS. Mitochondrial signal transduction. Cell Metab. 2022;34:1620–53.
  24. Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11:102.
  25. Santos JH. Mitochondria signaling to the epigenome: a novel role for an old organelle. Free Radic Biol Med. 2021;170:59–69.
  26. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58:495–505.
  27. Klemmensen MM, Borrowman SH, Pearce C, Pyles B. Mitochondrial dysfunction in neurodegenerative disorders. Neurotherapeutics. 2024;21: e00292.
  28. Manfredi G, Beal MF. The role of mitochondria in the pathogenesis of neurodegenerative diseases. CNS Spectr. 2000;10:426–72.
  29. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med. 2000;192:1001–14.
  30. Picard M, Turnbull DM. Linking the metabolic state and mitochondrial DNA in chronic disease, health, and aging. Diabetes. 2013;62:672–8.
  31. Naviaux RK. Mitochondrial and metabolic features of salugenesis and the healing cycle. Mitochondrion. 2023;70:131–63.
  32. Ludwig DS, Willett WC, Volek JS, Neuhouser ML. Dietary fat: From foe to friend? Science. 2018;362:764–70.
  33. Teicholz N, Croft SM, Cuaranta I, Cucuzzella M, Glandt M, Griauzde DH, et al. Myths and facts regarding low-carbohydrate diets. Nutrients. 2025;17:1047.
  34. Longo VD, Di Tano M, Mattson MP, Guidi N. Intermittent and periodic fasting, longevity and disease. Nat Aging. 2021;1:47–59.
  35. Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;2020(19):609–33.
  36. Cunnane SC, Courchesne-Loyer A, St-Pierre V, Valdenberghe C, Pierotti T, Fortier M, et al. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer’s disease. Ann N Y Acad Sci. 2016;1367:12–20.
  37. de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. 2019;381:2541–51.
  38. Gano LB, Patel M, Rho JM. Ketogenic diets, mitochondria, and neurological diseases. J Lipid Res. 2014;55:2211–28.
  39. Camandola S, Mattson MP. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 2017;36:1474–92.
  40. Taylor MK, Sullivan DK, Mahnken JD, Burns JM, Swerdlow RH. Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer’s disease. Alzheimers Dement. 2018;4:28–36.
  41. Brandt J, Buchholz A, Henry-Barron B, Vizthum D, Avramopoulos D, Cervenka MC. Preliminary report on the feasibility and efficacy of the modified Atkins diet for treatment of mild cognitive impairment and early Alzheimer’s disease. J Alzheimers Dis. 2019;68:969–81.
  42. Phillips MCL, Deprez LM, Mortimer GMN, Murtagh DKJ, McCoy S, Mylchreest R, et al. Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease. Alzheimers Res Ther. 2021;13:51.
  43. Buchholz A, Deme P, Betz JF, Brandt J, Haughey N, Cervenka MC. A randomized feasibility trial of the modified Atkins diet in older adults with mild cognitive impairment due to Alzheimer’s disease. Front Endocrinol. 2024;15:1182519.
  44. Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology. 2005;64:728–30.
  45. Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP. Low-fat versus ketogenic diet in Parkinson’s disease: a pilot randomized controlled trial. Mov Disord. 2018;33:1306–14.
  46. Krikorian R, Shidler MD, Summer SS, Sullivan PG, Duker AP, Isaacson RS, Espay AJ. Nutritional ketosis for mild cognitive impairment in Parkinson’s disease: a controlled pilot trial. Clin Park Relat Disord. 2019;1:41–7.
  47. Choi AH, Delgado M, Chen KY, Chung ST, Courville A, Turner SA, et al. A randomized feasibility trial of medium chain triglyceride-supplemented ketogenic diet in people with Parkinson’s disease. BMC Neurol. 2024;24:106.

Related topics